Psychometric Testing
Objective: Establish baseline cognitive function and psychiatric status in patients with Alzheimer's disease prior to enrollment in a blood-brain barrier opening study
Gather these items before starting the experiment. Check off items as you prepare.
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Patient screening and referral
Patients between age 50 and 85 with mild-to-moderate AD were referred to the study by neurologists and geriatricians
Note: Inclusion criteria: MMSE score equal to or greater than 18
View evidence from paper
“Patients between age 50 and 85 with mild-to-moderate AD with an MMSE score equal to or greater than 18 were eligible for the study. In general, patients were referred to the study by neurologists and geriatricians”
Informed consent
Prior to enrollment, all patients and their primary caregivers provided informed consent to the study and publication of radiologic images
View evidence from paper
“Prior to enrollment, all patients and their primary caregivers provided informed consent to the study, and publication of radiologic images”
Cognitive diagnosis confirmation
Confirmation of Alzheimer's disease diagnosis by an expert in cognitive neurology
View evidence from paper
“During screening, patients underwent confirmation of their diagnosis by an expert in cognitive neurology”
Pre-surgical anesthetic evaluation
Pre-surgical anesthetic evaluation conducted during screening phase
View evidence from paper
“During screening, patients underwent confirmation of their diagnosis by an expert in cognitive neurology, a pre-surgical anesthetic evaluation, baseline psychometric tests”
Baseline psychometric testing
Administration of baseline psychometric tests to establish cognitive function. Tests include Mini Mental State Exam (MMSE score 18-28), Short form Geriatric Depression Scale (score ≤6), and Modified Hachinski Ischemia Scale (score ≤4)
View evidence from paper
“baseline psychometric tests, and radiographic investigations with CT, MRI, and [18F]-florbetaben PET CT scans. Mini Mental State Exam 18–28, Short form Geriatric Depression Scale ≤6, Modified Hachinski Ischemia Scale ≤4”
Radiographic investigations
Patients underwent CT, MRI, and [18F]-florbetaben PET CT scans to assess for contraindications and confirm beta-amyloid deposition in the right frontal lobe
View evidence from paper
“radiographic investigations with CT, MRI, and [18F]-florbetaben PET CT scans”
Assessment of exclusion criteria
Evaluation of exclusion criteria including contraindications to MRI/contrast agents, MRI findings of active neurological processes, cardiac disease, hypertension, bleeding predisposition, cerebral/systemic vasculopathy, psychiatric symptoms on NPI-Q, renal function, and respiratory disorders
View evidence from paper
“They were excluded if they had any contraindications to MRI, gadolinium or ultrasound contrast (Definity®), increased risk of bleeding, active intracranial diseases such as brain tumors or vascular malformations, or significant cardiovascular, pulmonary, and renal disease”